Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 261 participants.
Also called NCT01294423
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 261 participants
- Sponsor
- Registry
-
NCT01294423
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01294423. Randomized; quadruple masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2013-08-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes
- Condition
- High Blood Sugar
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01294423- Content hash
b47afdf3b511e2dcd7d98572001d4d3b8ffa859f538185851f2ec2ae2b4baaba